Sionna Therapeutics (NASDAQ:SION) Director Sells $1,486,009.80 in Stock

Sionna Therapeutics, Inc. (NASDAQ:SION) Director Peter Thompson sold 33,356 shares of the business’s stock in a transaction that occurred on Wednesday, December 24th. The shares were sold at an average price of $44.55, for a total value of $1,486,009.80. Following the completion of the sale, the director directly owned 3,561,655 shares of the company’s stock, valued at approximately $158,671,730.25. The trade was a 0.93% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

Sionna Therapeutics Stock Down 2.0%

Shares of Sionna Therapeutics stock traded down $0.89 during midday trading on Monday, reaching $42.81. 133,694 shares of the company’s stock traded hands, compared to its average volume of 339,078. Sionna Therapeutics, Inc. has a 52 week low of $7.26 and a 52 week high of $45.00. The company’s 50 day simple moving average is $40.05 and its 200 day simple moving average is $28.35.

Sionna Therapeutics (NASDAQ:SION) last posted its earnings results on Wednesday, November 5th. The company reported ($0.46) EPS for the quarter, topping the consensus estimate of ($0.52) by $0.06.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on SION. Weiss Ratings reissued a “sell (e+)” rating on shares of Sionna Therapeutics in a research report on Monday, December 22nd. BTIG Research initiated coverage on shares of Sionna Therapeutics in a research report on Wednesday, November 19th. They set a “buy” rating and a $50.00 target price for the company. Wall Street Zen raised Sionna Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, December 13th. Jones Trading started coverage on Sionna Therapeutics in a research note on Monday, September 8th. They issued a “buy” rating and a $46.00 price objective on the stock. Finally, Raymond James Financial restated a “strong-buy” rating on shares of Sionna Therapeutics in a research note on Wednesday, November 5th. Two research analysts have rated the stock with a Strong Buy rating, five have given a Buy rating and two have issued a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $43.14.

Hedge Funds Weigh In On Sionna Therapeutics

Large investors have recently added to or reduced their stakes in the company. Russell Investments Group Ltd. bought a new stake in shares of Sionna Therapeutics in the 3rd quarter worth approximately $30,000. BNP Paribas Financial Markets bought a new position in Sionna Therapeutics in the second quarter worth $31,000. Police & Firemen s Retirement System of New Jersey bought a new position in Sionna Therapeutics in the second quarter worth $45,000. Virtus Investment Advisers LLC acquired a new stake in Sionna Therapeutics during the second quarter worth $96,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new stake in Sionna Therapeutics in the 2nd quarter valued at $117,000.

Sionna Therapeutics Company Profile

Sionna Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation RNA therapeutics for oncology and immunology indications. Leveraging proprietary lipid nanoparticle and coacervate delivery technologies, the company aims to overcome key challenges associated with stability, targeting and immune activation that have historically limited the clinical performance of mRNA-based medicines. Its strategic focus spans both solid tumors and hematological malignancies, as well as selected autoimmune disorders, reflecting a broad ambition to harness the power of messenger RNA in diverse therapeutic areas.

At the heart of Sionna’s approach is a platform that combines optimized ionizable lipids with bespoke surface chemistries to enhance payload delivery, intracellular release and endosomal escape.